105.40 +0.24 (0.23%)
After hours: 6:06PM EST
|Bid||105.40 x 300|
|Ask||105.59 x 2000|
|Day's Range||104.80 - 106.13|
|52 Week Range||94.55 - 147.17|
|PE Ratio (TTM)||32.57|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
After reporting less than expected growth, CELG stock tumbled hard, like, really hard. CELG still has everything you could want in a mature, cash-rich biotech stock, and now investors can snag it for a song. In the end, Celgene still has plenty of muscle behind it.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting CELG. Over the last one-month, outflows of investor capital in ETFs holding CELG totaled $1.32 billion.
Shares of large-cap biotechnology stocks as a group and as represented by the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) rallied on Thursday as a broader risk-on feel came back to the world of U.S. equities. As regular readers of this column know, higher-volatility groups of stocks and in particular biotechnology in my eye are better traded using an ETF to represent the group thematically. While I continue to like biotechnology and the IBB ETF thematically, through a multi-month lens, I don’t so much like to a) buy them at the top end of their trading ranges and b) don’t like all stocks in this space at any price.
After rising 15.4% in the first nine months of the year, the Medical-Biotech /Genetics industry has declined 13.4% so far in the fourth quarter.
Biotech behemoths like Celgene and Gilead struggled in the third quarter, leaving room for nimble innovators like Neurocrine, Exelixis and Juno Therapeutics to swipe headlines after crushing expectations.
Biotech and life sciences stocks have had a great run-up so far in 2017. Through the end of October, the S&P Biotechnology Select Sector Industry Index (SPSIBI) is up 52%. That makes the life science stocks some of best performers around. And what’s not to like?
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Celgene Corp. Here are 5 ETFs with the largest exposure to CELG-US. Comparing the performance and risk of Celgene Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Healthcare stocks are some of the most intriguing long-term stocks to buy. Picking up these stars now could end up being very profit-friendly.
If someone had told you at the beginning of the year that the Republican-controlled Congress was going to try and fail to repeal and replace the Affordable Care Act (ACA) multiple times during 2017, you probably wouldn’t have believed them. You might think that this uncertainty would have taken a bearish toll on healthcare stocks, but you’d be wrong in most cases. Many healthcare stocks are keeping pace with, or outperforming, the S&P 500.
The recent sell-off has made Celgene stock a bargain. But that's not the only reason why it's smart to buy this biotech.
A market capitalization of USD $80.03B puts Celgene Corporation (NASDAQ:CELG) in the basket of stocks categorized as large-caps. These stocks draw significant attention from the investing community due to itsRead More...
The October 31 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
Of the 31 analysts tracking Celgene (CELG) in November 2017, 11 analysts recommended a “strong buy” while eight analysts recommended a “buy.”